Capricor Therapeutics (CAPR) AI Stock Analysis

• Market Cap: $1.60B
• Dividend Yield: N/A
• Average Volume (3M): 4.43M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.23
• Revenue Growth: -52.08%
• EPS Growth: -69.35%
• Country: US
• Employees: 160
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.54
• Shares Outstanding: 54,400,784
• 10 Day Avg. Volume: 1,975,774
• 30 Day Avg. Volume: 4,434,605
• PEG Ratio: -0.31
• Price to Book (P/B): 3.34
• Price to Sales (P/S): 21.82
• P/FCF Ratio: -11.70
• Enterprise Value/Market Cap: 0.16
• Enterprise Value/Revenue: 22.37
• Enterprise Value/Gross Profit: -3.85
• Enterprise Value/Ebitda: -2.99
• 1Y Price Target: $48.75
• Price Target Upside: 68.69% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -2.13
• Revenue Forecast (FY): $737.50K

• Rating: 57 Neutral
• Price Target: $30.00 ▲(3.81% Upside)

Capricor Therapeutics' overall score is primarily influenced by its financial challenges, including ongoing losses and cash flow issues. However, strong technical indicators and positive clinical trial results provide some optimism. The valuation remains a concern, but the potential for regulatory approval and commercialization could improve the outlook.

Positive Factors

Clinical Trial Success

The successful HOPE-3 trial results enhance Capricor's market position and increase the likelihood of regulatory approval, potentially leading to new treatment options and revenue streams.

Strong Safety Profile

A consistent safety profile supports long-term viability and market acceptance of Daramycin, reducing regulatory risks and enhancing patient trust.

Strategic Partnerships

Strategic partnerships provide financial stability and resources for product development, enhancing Capricor's ability to bring therapies to market.

Negative Factors

Revenue Decline

The absence of revenue in 2025 highlights challenges in generating consistent income, impacting financial sustainability and operational funding.

Increased Operating Expenses

Rising operating expenses strain financial resources, potentially limiting investment in growth initiatives and affecting profitability.

Regulatory Challenges

Regulatory hurdles delay product approval and market entry, increasing costs and uncertainty in achieving commercial success.

Capricor Therapeutics Business Overview & Revenue Model

Company Description

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders. Its lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase III clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); and CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with SARS-CoV-2. The company also develops CAP-2003 that is in pre-clinical development for the treatment of trauma related injuries and conditions; and two vaccine candidates, which are in development stage for the potential prevention of COVID-19. It collaborates with Lonza Houston, Inc. for the clinical manufacturing of CAP-1002, its cell therapy candidate for the treatment of DMD and other indications. The company was founded in 2005 and is headquartered in San Diego, California.

How the Company Makes Money

Capricor Therapeutics generates revenue through a combination of research and development funding, grants, and potential future product sales. The company may receive funding through collaborations and partnerships with pharmaceutical companies, which can provide upfront payments, milestone payments based on the achievement of specific development goals, and royalties on future sales of any resulting products. Additionally, Capricor seeks government grants and funding from research institutions to support its clinical trials and research efforts. Their strategic partnerships can also open avenues for co-development or licensing agreements that contribute to their revenue streams.

Capricor Therapeutics Financial Statement Overview

Summary

Capricor Therapeutics faces significant financial challenges typical of the biotechnology sector, with negative profitability and cash flow issues despite a strong equity position. Revenue growth is present but overshadowed by operational inefficiencies and persistent losses.

Income Statement

Capricor Therapeutics has shown significant revenue volatility over the years, with a notable increase in revenue in 2023 compared to previous years, but still operates at a net loss. The gross profit margin is consistently negative, and the EBIT and EBITDA margins are also negative, indicating the company is struggling with profitability. Revenue growth is present but overshadowed by operational inefficiencies and high expenses.

Balance Sheet

The company has a strong equity position with a positive stockholders' equity, and the absence of total debt in the latest year indicates reduced leverage risk. However, the negative total liabilities figure in 2024 raises concerns about data accuracy or financial reporting issues. The equity ratio is favorable given the high equity levels in relation to assets.

Cash Flow

Capricor Therapeutics has experienced fluctuating cash flow from operations, with periods of negative free cash flow, indicating challenges in generating sustainable cash from operations. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is not calculable, highlighting ongoing cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.13M	22.27M	25.18M	2.55M	244.90K	310.25K
Gross Profit	-64.75M	-27.70M	-11.27M	-19.27M	244.90K	310.25K
EBITDA	-83.21M	-41.14M	-23.01M	-29.16M	-20.69M	-13.55M
Net Income	-81.99M	-40.47M	-22.29M	-29.02M	-20.02M	-13.66M
Balance Sheet
Total Assets	126.44M	170.48M	58.73M	50.09M	41.33M	34.62M
Cash, Cash Equivalents and Short-Term Investments	98.57M	151.52M	39.49M	41.42M	34.89M	32.67M
Total Debt	14.54M	1.45M	2.24M	2.56M	2.87M	318.16K
Total Liabilities	42.57M	25.02M	36.13M	38.31M	9.96M	6.42M
Stockholders Equity	83.87M	145.46M	22.60M	11.79M	31.37M	28.20M
Cash Flow
Free Cash Flow	-44.68M	-41.53M	-27.64M	1.56M	-18.01M	-10.60M
Operating Cash Flow	-41.35M	-40.00M	-25.60M	4.92M	-16.81M	-10.05M
Investing Cash Flow	-84.94M	-116.18M	5.11M	-35.07M	-1.20M	5.44M
Financing Cash Flow	81.16M	152.77M	25.58M	4.87M	20.23M	33.38M

Capricor Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 28.90
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPR, the sentiment is Positive. The current price of 28.9 is above the 20-day moving average (MA) of 21.97, above the 50-day MA of 12.42, and above the 200-day MA of 10.02, indicating a bullish trend. The MACD of 5.16 indicates Negative momentum. The RSI at 72.79 is Negative, neither overbought nor oversold. The STOCH value of 73.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CAPR.

Capricor Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDMT	60 Neutral	$497.65M	-2.01	-45.38%	―	―	―
CAPR	57 Neutral	$1.60B	-16.07	-107.79%	―	-52.08%	-69.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALEC	46 Neutral	$158.27M	-1.32	-121.98%	―	12.26%	37.36%
IMAB	45 Neutral	―	―	―	―	-100.00%	72.45%
HUMA	42 Neutral	$206.51M	-4.73	―	―	―	82.23%
GALT	35 Underperform	$259.85M	-6.75	―	―	―	18.82%

Capricor Therapeutics Corporate Events

Capricor Therapeutics Announces $150 Million Public Offering

On December 5, 2025, Capricor Therapeutics announced the pricing of a public offering of 6,000,000 shares of common stock at $25.00 per share, expected to generate gross proceeds of $150 million. The proceeds will support the development and manufacturing of product candidates, working capital, and general corporate purposes, with the offering anticipated to close on December 8, 2025, subject to customary conditions.

Capricor Therapeutics Reports Positive HOPE-3 Trial Results

On December 3, 2025, Capricor Therapeutics provided an update on the top-line results from its HOPE-3 Phase 3 trial during a conference call. The trial, which involved 106 patients, focused on the efficacy and safety of Deramiocel for treating Duchenne muscular dystrophy. The results indicated significant improvements in skeletal muscle function and cardiac endpoints, confirming the findings of previous trials. The trial met its primary and key secondary endpoints, demonstrating a favorable long-term safety profile and sustained efficacy over four years. This development could potentially enhance Capricor’s position in the biotechnology industry and provide new treatment options for patients with high unmet needs.

Capricor Therapeutics Announces Positive Phase 3 Trial Results

On December 3, 2025, Capricor Therapeutics announced positive topline results from its pivotal Phase 3 HOPE-3 clinical trial evaluating Deramiocel in boys and young men with Duchenne muscular dystrophy. The trial demonstrated statistically significant improvements in both skeletal and cardiac function, meeting its primary and key secondary endpoints. These results highlight Deramiocel’s potential as a first-in-class therapy for Duchenne cardiomyopathy, a leading cause of mortality in DMD. The company, in collaboration with its commercial partner Nippon Shinyaku, is advancing launch readiness activities to support patient access, pending regulatory approval.